<DOC>
	<DOCNO>NCT02157883</DOCNO>
	<brief_summary>This 2 part study patient EGFRm+ non small cell lung cancer ( NSCLC ) , whose disease progress EGFRm TKI , refractory resistant standard therapy . Part A assess effect multiple oral dos itraconazole single dose pharmacokinetic ( PK ) parameter AZD9291 . On completion Part A , patient may continue take AZD9291 tablet ( Part B ) follow collection 216 hour sample Day 19 Investigator deem appropriate , time disease progress , Investigator believe long derive clinical benefit , stop take AZD9291 reason .</brief_summary>
	<brief_title>Study Assess Effect Itraconazole ( CYP3A4 Inhibitor ) Pharmacokinetics AZD9291 , Patients With EGFR Positive Non-small Cell Lung Cancer . Patients Will Chosen From Those Who Have Already Been Prescribed EGFR TKI Medicine ( Such Iressa Tarceva )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cytochrome P-450 CYP3A Inhibitors</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Osimertinib</mesh_term>
	<criteria>For inclusion study , patient fulfil follow criterion : 1 . Male female , age least 18 year . 2 . Histological cytological confirmation diagnosis NSCLC . 3 . Radiological documentation disease progression previous continuous treatment EGFR TKI , eg , gefitinib erlotinib . In addition , line therapy may give . All patient must document radiological progression last treatment administer prior enrol study . 4 . Confirmation tumour harbour EGFR mutation know associated EGFR TKI sensitivity ( include G719X , exon 19 deletion , L858R , L861Q ) . 5 . ECOG performance status 01 deterioration previous 2 week . 6 . Patients must life expectancy â‰¥12 week estimate time screening . 7 . Evidence nonchildbearing status woman childbearing potential , postmenopausal status : negative urine serum pregnancy test within 28 day study treatment , confirm prior treatment Day 1 Part A , post menopausal status . Females use adequate contraceptive measure must negative pregnancy test prior start dose childbearing potential must evidence nonchildbearing potential fulfil one follow criterion screen : postmenopausal define age 50 year amenorrhoeic least 12 month follow cessation exogenous hormonal treatment ; woman 50 year old would consider postmenopausal amenorrhoeic 12 month follow cessation exogenous hormonal treatment LH FSH level postmenopausal range institution ; documentation irreversible surgical sterilisation hysterectomy , bilateral oophorectomy bilateral salpingectomy tubal ligation . 8 . Male patient willing use barrier contraception , ie , condom , 6 month last study drug take . Patients enter study follow exclusion criterion fulfil : 1 . Participation another clinical study IP last 14 day ( long period depend defined characteristic agent use ) . 2 . Treatment follow : Treatment EGFR TKI w/in 8 day approximately 5x halflife , whichever longer , first dose study treatment ; Any cytotoxic chemotherapy , investigational agent anticancer drug w/in 14 day first dose study treatment ; Major surgery ( exclude placement vascular access ) within 4 week first dose ; Radiotherapy limit field radiation palliation within 1 week first dose study treatment , exception patient receive radiation 30 % bone marrow wide field radiation must complete within 4 week first dose study treatment ; Patients currently receive ( unable stop use prior receiving first dose study treatment ) medication herbal supplement know potent inhibitor CYP2C8 CYP3A4 ( least 1 week prior ) potent inducer CYP3A4 ( least 3 week prior ) . All patient must try avoid concomitant use medication , herbal supplement and/or ingestion food know inducer/inhibitory effect CYP3A4 , CYP2C8 , and/ CYP1A2 . 3 . Any unresolved toxicity prior therapy great CTCAE Grade 1 time start study treatment exception alopecia Grade 2 , prior platinumtherapy relate neuropathy . 4 . Any intake grapefruit , grapefruit juice , Seville oranges , Seville orange marmalade , product contain grapefruit Seville oranges within 7 day first administration IP end Part A . 5 . Spinal cord compression brain metastasis unless asymptomatic , stable require steroid least 4 week prior start study treatment . 6 . Any evidence severe uncontrolled systemic disease , include uncontrolled hypertension active bleeding diatheses , Investigator 's opinion make undesirable patient participate study would jeopardise compliance protocol , active infection include hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) . Screening chronic condition require . 7 . Inadequate bone marrow reserve organ function demonstrate follow laboratory value : ANC &lt; 1.5 x 10^9/L ; Platelet count &lt; 100 x 10^9/L ; Haemoglobin &lt; 90 g/L ; ALT &gt; 2.5 x institutional ULN demonstrable liver metastasis &gt; 5 x institutional ULN presence liver metastases ; AST &gt; 2.5 x institutional ULN demonstrable liver metastasis &gt; 5 x institutional ULN presence liver metastases ; Total bilirubin &gt; 1.5 x institutional ULN liver metastases &gt; 3 x institutional ULN presence document Gilbert 's Syndrome liver metastasis ; Creatinine &gt; 1.5 x institutional ULN concurrent creatinine clearance &lt; 50 mL/min ( measure calculate CockcroftGault formula ) ; confirmation creatinine clearance require creatinine &gt; 1.5 x institutional ULN . 8 . Any following cardiac criterion : Mean rest correct QT interval correct heart rate use Fridericia 's correction factor ( QTcF ) &gt; 450 msec obtain 3 ECGs ; Any clinically important abnormality rhythm , conduction morphology rest ECG eg , complete leave bundle branch block , third degree heart block , second degree heart block , PR interval &gt; 250 msec ; Any factor increase risk QTc prolongation risk arrhythmic event heart failure , hypokalaemia , congenital long QT syndrome , family history long QT syndrome unexplained sudden death 40 year age concomitant medication know prolong QT interval . 9 . Patients unable swallow oral medication patient GI disorder significant GI resection likely interfere absorption AZD9291 . 10 . Past medical history interstitial lung disease ( ILD ) , druginduced ILD , radiation pneumonitis require steroid treatment , evidence clinically active ILD . 11 . Women breastfeed . 12 . Patients know hypersensitivity AZD9291 itranconazole excipients . 12 . Concomitant medication contraindicate use itraconazole ( include , limited ) : cisapride , oral midazolam , nisoldipine , pimozide , quinidine , dofetilide , triazolam , levacetylmethadol ( levomethadyl ) , 3hydroxy3methylglutaryl coenzyme A ( HMGCoA ) reductase inhibitor metabolize CYP3A4 , lovastatin simvastatin , ergot alkaloid metabolize CYP3A4 , dihydroergotamine , ergometrine ( ergonovine ) , ergotamine methylergometrine ( methylergonovine ) . 13 . For optional genetic research : Previous allogenic bone marrow transplant nonleukocyte deplete whole blood transfusion within 120 day sample collection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>oncology , cancer , non small cell lung cancer , anticancer drug , pharmacokinetics , AZD9291 , intraconazole , EGFR sensitivity mutation</keyword>
</DOC>